Chi­nese VC syn­di­cates wa­ger $172M on As­cen­t­age and As­cle­tis, flag­ging a new trend

Here’s an­oth­er trend to pay close at­ten­tion to in 2017: Chi­nese biotechs are in­creas­ing­ly able to tap in­to lo­cal, state-backed ven­ture syn­di­cates for some big …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.